Development:
2006 on the basis of 6288 men screened within the Dutch part of the European Randomized study of Screening for Prostate Cancer (ERSPC)
Patent filed in 2006.
| Publications: | Kranse et al. Prostate 2008 Steyerberg et al. J Urol 2007 |
Application:
Estimation of capability to avoid unnecessary biopsies and to increase detection of potentially aggressive prostate cancer.
| Publications: | Bul et al. Canadian J Urol, 2011 (based on autopsy data, the RC # 6 is suitable for contemporary biopsy schemes) Roobol et al. Eur Urol 2012 (A RC should contain information on volume, either based on TRUS or DRE) Roobol et al. World J Urol 2012 (The ERSPC DRE-based RC provided net benefit over PSA and DRE) Roobol et al. Abstract 145, EAU meeting 2012 (The 4-year risk calculator is a promising tool in reducing uncertainty, unnecessary testing and overdiagnosis) |
New Features:
Updating to contemporary biopsy schemes, introducing a new risk calculator based on DRE, and future risk prediction.
| Publications: | Bul et al. Canadian J Urol, 2011 (based on autopsy data, the RC # 6 is suitable for contemporary biopsy schemes) Roobol et al. Eur Urol 2012 (A RC should contain information on volume, either based on TRUS or DRE) Roobol et al. World J Urol 2012 (The ERSPC DRE-based RC provided net benefit over PSA and DRE) Roobol et al. Abstract 145, EAU meeting 2012 (The 4-year risk calculator is a promising tool in reducing uncertainty, unnecessary testing and overdiagnosis) |
Validation:
How does the tool perform in other settings, populations.
| Publications: | van Vugt et al. Eur J Cancer 2011 (AUC’s of 0.76 and 0.78 in different screening settings) Cavadas et al, Eur Urol 2010 (ERSPC RC outperformed the PCPT RC in a contemporary cohort of screened patients (AUC 0.80)) Yoon et al, prostate 2011 (The ERSPC RC performs well (AUC 0.88) but overestimates risk in Asian men) Trottier et al, 2011 (The ERSPC RC outperformed the PCPT RC in a Canadian clinical cohort) |
| Publications: | van Vugt et al. BJUI 2011 (Compliance of both urologists and patients with the RC recommendation is 83%) Van Vugt et al. Submitted. (Implementation of the ERSPC RC in clinical practice leads to an increase of the PPV to 68%) |
Additional data (more)
Click here to go to the